Patients with an advanced degree of CKD were not more frequently predisposed to a premature interruption of P2Y12 inhibitor treatment, although they were more probable to temporarily discontinue the treatment with P2Y12 inhibitor because serious bruising or bleeding and to change the treatment than patients with less serious or no CKD [167]. This evidence concerns the gene P2RY12 and chronic kidney disease.